nodes	percent_of_prediction	percent_of_DWPC	metapath
Rasagiline—BCL2—esophageal cancer	0.757	1	CbGaD
Rasagiline—BCL2—neck—esophageal cancer	0.00395	0.215	CbGeAlD
Rasagiline—BCL2—epithelium—esophageal cancer	0.00269	0.146	CbGeAlD
Rasagiline—BCL2—smooth muscle tissue—esophageal cancer	0.00259	0.141	CbGeAlD
Rasagiline—BCL2—digestive system—esophageal cancer	0.00205	0.111	CbGeAlD
Rasagiline—BCL2—lung—esophageal cancer	0.00171	0.0927	CbGeAlD
Rasagiline—BCL2—lymph node—esophageal cancer	0.00117	0.0634	CbGeAlD
Rasagiline—MAOB—bronchus—esophageal cancer	0.0011	0.0599	CbGeAlD
Rasagiline—MAOB—digestive system—esophageal cancer	0.000852	0.0462	CbGeAlD
Rasagiline—MAOB—lung—esophageal cancer	0.000712	0.0386	CbGeAlD
Rasagiline—CYP1A2—digestive system—esophageal cancer	0.000607	0.0329	CbGeAlD
Rasagiline—CYP1A2—lung—esophageal cancer	0.000507	0.0275	CbGeAlD
Rasagiline—MAOB—lymph node—esophageal cancer	0.000487	0.0264	CbGeAlD
Rasagiline—Orthostatic hypotension—Cisplatin—esophageal cancer	0.000372	0.00377	CcSEcCtD
Rasagiline—Apnoea—Methotrexate—esophageal cancer	0.000363	0.00368	CcSEcCtD
Rasagiline—Phlebitis—Capecitabine—esophageal cancer	0.000348	0.00353	CcSEcCtD
Rasagiline—Thrombophlebitis—Capecitabine—esophageal cancer	0.000347	0.00352	CcSEcCtD
Rasagiline—Polyuria—Capecitabine—esophageal cancer	0.000342	0.00347	CcSEcCtD
Rasagiline—Gastroenteritis—Capecitabine—esophageal cancer	0.000339	0.00344	CcSEcCtD
Rasagiline—Deafness—Capecitabine—esophageal cancer	0.000335	0.0034	CcSEcCtD
Rasagiline—Vascular purpura—Capecitabine—esophageal cancer	0.000335	0.0034	CcSEcCtD
Rasagiline—Eye pain—Capecitabine—esophageal cancer	0.000332	0.00337	CcSEcCtD
Rasagiline—Dysarthria—Methotrexate—esophageal cancer	0.000325	0.0033	CcSEcCtD
Rasagiline—Renal failure acute—Capecitabine—esophageal cancer	0.000325	0.0033	CcSEcCtD
Rasagiline—Libido decreased—Capecitabine—esophageal cancer	0.000324	0.00328	CcSEcCtD
Rasagiline—Amnesia—Capecitabine—esophageal cancer	0.000319	0.00324	CcSEcCtD
Rasagiline—Dermatitis exfoliative—Capecitabine—esophageal cancer	0.000318	0.00323	CcSEcCtD
Rasagiline—Dermatitis bullous—Capecitabine—esophageal cancer	0.000314	0.00319	CcSEcCtD
Rasagiline—Purpura—Capecitabine—esophageal cancer	0.000311	0.00316	CcSEcCtD
Rasagiline—Acute coronary syndrome—Cisplatin—esophageal cancer	0.000309	0.00314	CcSEcCtD
Rasagiline—Arthritis—Capecitabine—esophageal cancer	0.000309	0.00313	CcSEcCtD
Rasagiline—Vaginal inflammation—Methotrexate—esophageal cancer	0.000308	0.00312	CcSEcCtD
Rasagiline—Myocardial infarction—Cisplatin—esophageal cancer	0.000308	0.00312	CcSEcCtD
Rasagiline—Neuropathy peripheral—Cisplatin—esophageal cancer	0.000308	0.00312	CcSEcCtD
Rasagiline—Cardiac failure—Capecitabine—esophageal cancer	0.000308	0.00312	CcSEcCtD
Rasagiline—Cerebrovascular accident—Capecitabine—esophageal cancer	0.000306	0.00311	CcSEcCtD
Rasagiline—Stomatitis—Cisplatin—esophageal cancer	0.000306	0.0031	CcSEcCtD
Rasagiline—Conjunctivitis—Cisplatin—esophageal cancer	0.000305	0.00309	CcSEcCtD
Rasagiline—Melaena—Methotrexate—esophageal cancer	0.000301	0.00305	CcSEcCtD
Rasagiline—Diplopia—Capecitabine—esophageal cancer	0.0003	0.00305	CcSEcCtD
Rasagiline—Gastrointestinal haemorrhage—Capecitabine—esophageal cancer	0.0003	0.00305	CcSEcCtD
Rasagiline—Osteoarthritis—Capecitabine—esophageal cancer	0.0003	0.00305	CcSEcCtD
Rasagiline—Disturbance in sexual arousal—Capecitabine—esophageal cancer	0.000298	0.00302	CcSEcCtD
Rasagiline—Depressed level of consciousness—Methotrexate—esophageal cancer	0.000297	0.00302	CcSEcCtD
Rasagiline—Migraine—Capecitabine—esophageal cancer	0.000295	0.003	CcSEcCtD
Rasagiline—Vaginal infection—Methotrexate—esophageal cancer	0.000291	0.00295	CcSEcCtD
Rasagiline—Face oedema—Capecitabine—esophageal cancer	0.00029	0.00294	CcSEcCtD
Rasagiline—Urinary retention—Capecitabine—esophageal cancer	0.000285	0.0029	CcSEcCtD
Rasagiline—Mood swings—Capecitabine—esophageal cancer	0.000284	0.00288	CcSEcCtD
Rasagiline—Ataxia—Capecitabine—esophageal cancer	0.000282	0.00286	CcSEcCtD
Rasagiline—Ecchymosis—Methotrexate—esophageal cancer	0.000278	0.00282	CcSEcCtD
Rasagiline—Mouth ulceration—Methotrexate—esophageal cancer	0.000278	0.00282	CcSEcCtD
Rasagiline—Neoplasm—Methotrexate—esophageal cancer	0.000278	0.00282	CcSEcCtD
Rasagiline—Urine output increased—Methotrexate—esophageal cancer	0.000278	0.00282	CcSEcCtD
Rasagiline—Urinary tract disorder—Cisplatin—esophageal cancer	0.000278	0.00282	CcSEcCtD
Rasagiline—Liver function test abnormal—Capecitabine—esophageal cancer	0.000277	0.00281	CcSEcCtD
Rasagiline—Connective tissue disorder—Cisplatin—esophageal cancer	0.000277	0.00281	CcSEcCtD
Rasagiline—Urethral disorder—Cisplatin—esophageal cancer	0.000276	0.0028	CcSEcCtD
Rasagiline—Gynaecomastia—Methotrexate—esophageal cancer	0.000275	0.00279	CcSEcCtD
Rasagiline—Orthostatic hypotension—Capecitabine—esophageal cancer	0.000274	0.00278	CcSEcCtD
Rasagiline—Muscular weakness—Capecitabine—esophageal cancer	0.000265	0.00269	CcSEcCtD
Rasagiline—Eye disorder—Cisplatin—esophageal cancer	0.000263	0.00267	CcSEcCtD
Rasagiline—Cardiac disorder—Cisplatin—esophageal cancer	0.000261	0.00265	CcSEcCtD
Rasagiline—Asthma—Capecitabine—esophageal cancer	0.000259	0.00263	CcSEcCtD
Rasagiline—Influenza—Capecitabine—esophageal cancer	0.000259	0.00263	CcSEcCtD
Rasagiline—Dysphagia—Capecitabine—esophageal cancer	0.000259	0.00263	CcSEcCtD
Rasagiline—Thrombophlebitis—Methotrexate—esophageal cancer	0.000258	0.00262	CcSEcCtD
Rasagiline—Polyuria—Methotrexate—esophageal cancer	0.000254	0.00258	CcSEcCtD
Rasagiline—Immune system disorder—Cisplatin—esophageal cancer	0.000254	0.00258	CcSEcCtD
Rasagiline—Mediastinal disorder—Cisplatin—esophageal cancer	0.000254	0.00258	CcSEcCtD
Rasagiline—Angina pectoris—Capecitabine—esophageal cancer	0.000253	0.00256	CcSEcCtD
Rasagiline—Alopecia—Cisplatin—esophageal cancer	0.000249	0.00253	CcSEcCtD
Rasagiline—Malnutrition—Cisplatin—esophageal cancer	0.000245	0.00249	CcSEcCtD
Rasagiline—Dysuria—Capecitabine—esophageal cancer	0.000243	0.00246	CcSEcCtD
Rasagiline—Renal failure acute—Methotrexate—esophageal cancer	0.000242	0.00246	CcSEcCtD
Rasagiline—Flatulence—Cisplatin—esophageal cancer	0.000242	0.00245	CcSEcCtD
Rasagiline—Upper respiratory tract infection—Capecitabine—esophageal cancer	0.000241	0.00245	CcSEcCtD
Rasagiline—CYP1A2—Cytochrome P450 - arranged by substrate type—CYP26A1—esophageal cancer	0.000239	0.00189	CbGpPWpGaD
Rasagiline—BCL2—ATF-2 transcription factor network—CCND1—esophageal cancer	0.000237	0.00188	CbGpPWpGaD
Rasagiline—CYP1A2—Phase 1 - Functionalization of compounds—ADH7—esophageal cancer	0.000237	0.00188	CbGpPWpGaD
Rasagiline—Dermatitis exfoliative—Methotrexate—esophageal cancer	0.000237	0.0024	CcSEcCtD
Rasagiline—Photosensitivity reaction—Capecitabine—esophageal cancer	0.000237	0.0024	CcSEcCtD
Rasagiline—Muscle spasms—Cisplatin—esophageal cancer	0.000236	0.00239	CcSEcCtD
Rasagiline—CYP1A2—Oxidation by Cytochrome P450—CYP26A1—esophageal cancer	0.000236	0.00187	CbGpPWpGaD
Rasagiline—BCL2—IL2 signaling events mediated by PI3K—PIK3CA—esophageal cancer	0.000235	0.00186	CbGpPWpGaD
Rasagiline—Weight decreased—Capecitabine—esophageal cancer	0.000235	0.00238	CcSEcCtD
Rasagiline—BCL2—Role of Calcineurin-dependent NFAT signaling in lymphocytes—EP300—esophageal cancer	0.000235	0.00186	CbGpPWpGaD
Rasagiline—BCL2—Integrated Breast Cancer Pathway—ABL1—esophageal cancer	0.000234	0.00185	CbGpPWpGaD
Rasagiline—Infestation NOS—Capecitabine—esophageal cancer	0.000231	0.00235	CcSEcCtD
Rasagiline—Infestation—Capecitabine—esophageal cancer	0.000231	0.00235	CcSEcCtD
Rasagiline—Depression—Capecitabine—esophageal cancer	0.000231	0.00234	CcSEcCtD
Rasagiline—Tremor—Cisplatin—esophageal cancer	0.00023	0.00233	CcSEcCtD
Rasagiline—BCL2—Integrated Pancreatic Cancer Pathway—CHEK2—esophageal cancer	0.000229	0.00181	CbGpPWpGaD
Rasagiline—Acute coronary syndrome—Capecitabine—esophageal cancer	0.000228	0.00231	CcSEcCtD
Rasagiline—Cerebrovascular accident—Methotrexate—esophageal cancer	0.000228	0.00231	CcSEcCtD
Rasagiline—BCL2—Apoptosis Modulation and Signaling—CASP8—esophageal cancer	0.000228	0.00181	CbGpPWpGaD
Rasagiline—BCL2—Direct p53 effectors—BAX—esophageal cancer	0.000228	0.0018	CbGpPWpGaD
Rasagiline—Ill-defined disorder—Cisplatin—esophageal cancer	0.000227	0.00231	CcSEcCtD
Rasagiline—Myocardial infarction—Capecitabine—esophageal cancer	0.000227	0.0023	CcSEcCtD
Rasagiline—Neuropathy peripheral—Capecitabine—esophageal cancer	0.000227	0.0023	CcSEcCtD
Rasagiline—Anaemia—Cisplatin—esophageal cancer	0.000227	0.0023	CcSEcCtD
Rasagiline—BCL2—Integrated Breast Cancer Pathway—SMAD4—esophageal cancer	0.000226	0.00179	CbGpPWpGaD
Rasagiline—Jaundice—Capecitabine—esophageal cancer	0.000225	0.00229	CcSEcCtD
Rasagiline—Stomatitis—Capecitabine—esophageal cancer	0.000225	0.00229	CcSEcCtD
Rasagiline—BCL2—Validated targets of C-MYC transcriptional repression—CCND1—esophageal cancer	0.000225	0.00178	CbGpPWpGaD
Rasagiline—Conjunctivitis—Capecitabine—esophageal cancer	0.000225	0.00228	CcSEcCtD
Rasagiline—BCL2—Ceramide signaling pathway—MYC—esophageal cancer	0.000225	0.00178	CbGpPWpGaD
Rasagiline—CYP1A2—Tryptophan metabolism—ALDH2—esophageal cancer	0.000224	0.00177	CbGpPWpGaD
Rasagiline—Osteoarthritis—Methotrexate—esophageal cancer	0.000223	0.00227	CcSEcCtD
Rasagiline—BCL2—Intrinsic Pathway for Apoptosis—TP53—esophageal cancer	0.000222	0.00176	CbGpPWpGaD
Rasagiline—BCL2—Amyotrophic lateral sclerosis (ALS)—TP53—esophageal cancer	0.000222	0.00176	CbGpPWpGaD
Rasagiline—Malaise—Cisplatin—esophageal cancer	0.000221	0.00224	CcSEcCtD
Rasagiline—Haematuria—Capecitabine—esophageal cancer	0.000221	0.00224	CcSEcCtD
Rasagiline—Leukopenia—Cisplatin—esophageal cancer	0.000219	0.00223	CcSEcCtD
Rasagiline—BCL2—ATF-2 transcription factor network—EP300—esophageal cancer	0.000219	0.00173	CbGpPWpGaD
Rasagiline—BCL2—Kit receptor signaling pathway—EP300—esophageal cancer	0.000219	0.00173	CbGpPWpGaD
Rasagiline—Epistaxis—Capecitabine—esophageal cancer	0.000218	0.00221	CcSEcCtD
Rasagiline—BCL2—Validated targets of C-MYC transcriptional repression—CDKN1A—esophageal cancer	0.000218	0.00173	CbGpPWpGaD
Rasagiline—BCL2—Integrated Breast Cancer Pathway—BAX—esophageal cancer	0.000214	0.0017	CbGpPWpGaD
Rasagiline—Convulsion—Cisplatin—esophageal cancer	0.000212	0.00216	CcSEcCtD
Rasagiline—BCL2—Apoptosis—CDKN2A—esophageal cancer	0.000212	0.00168	CbGpPWpGaD
Rasagiline—BCL2—C-MYB transcription factor network—CDKN2A—esophageal cancer	0.000212	0.00168	CbGpPWpGaD
Rasagiline—Mood swings—Methotrexate—esophageal cancer	0.000212	0.00215	CcSEcCtD
Rasagiline—Ataxia—Methotrexate—esophageal cancer	0.00021	0.00213	CcSEcCtD
Rasagiline—BCL2—Apoptosis—BAX—esophageal cancer	0.00021	0.00166	CbGpPWpGaD
Rasagiline—Haemoglobin—Capecitabine—esophageal cancer	0.000209	0.00212	CcSEcCtD
Rasagiline—Rhinitis—Capecitabine—esophageal cancer	0.000208	0.00211	CcSEcCtD
Rasagiline—CYP1A2—Phase 1 - Functionalization of compounds—ADH1B—esophageal cancer	0.000208	0.00165	CbGpPWpGaD
Rasagiline—Anxiety—Cisplatin—esophageal cancer	0.000208	0.00211	CcSEcCtD
Rasagiline—Haemorrhage—Capecitabine—esophageal cancer	0.000208	0.00211	CcSEcCtD
Rasagiline—BCL2—Validated targets of C-MYC transcriptional repression—EP300—esophageal cancer	0.000207	0.00164	CbGpPWpGaD
Rasagiline—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—esophageal cancer	0.000207	0.0021	CcSEcCtD
Rasagiline—Hypoaesthesia—Capecitabine—esophageal cancer	0.000207	0.0021	CcSEcCtD
Rasagiline—Liver function test abnormal—Methotrexate—esophageal cancer	0.000206	0.00209	CcSEcCtD
Rasagiline—Discomfort—Cisplatin—esophageal cancer	0.000206	0.00209	CcSEcCtD
Rasagiline—Urinary tract disorder—Capecitabine—esophageal cancer	0.000205	0.00208	CcSEcCtD
Rasagiline—Oedema peripheral—Capecitabine—esophageal cancer	0.000205	0.00208	CcSEcCtD
Rasagiline—BCL2—IL2-mediated signaling events—MYC—esophageal cancer	0.000204	0.00162	CbGpPWpGaD
Rasagiline—Connective tissue disorder—Capecitabine—esophageal cancer	0.000204	0.00207	CcSEcCtD
Rasagiline—Urethral disorder—Capecitabine—esophageal cancer	0.000204	0.00207	CcSEcCtD
Rasagiline—BCL2—Senescence and Autophagy in Cancer—RB1—esophageal cancer	0.000202	0.0016	CbGpPWpGaD
Rasagiline—BCL2—Corticotropin-releasing hormone—NOS3—esophageal cancer	0.000201	0.0016	CbGpPWpGaD
Rasagiline—Infection—Cisplatin—esophageal cancer	0.000199	0.00202	CcSEcCtD
Rasagiline—BCL2—Apoptosis Modulation and Signaling—CDKN2A—esophageal cancer	0.000199	0.00157	CbGpPWpGaD
Rasagiline—BCL2—C-MYB transcription factor network—PTGS2—esophageal cancer	0.000198	0.00157	CbGpPWpGaD
Rasagiline—BCL2—Integrated Cancer Pathway—TP53—esophageal cancer	0.000198	0.00157	CbGpPWpGaD
Rasagiline—Nervous system disorder—Cisplatin—esophageal cancer	0.000196	0.00199	CcSEcCtD
Rasagiline—BCL2—Immune System—RNF6—esophageal cancer	0.000195	0.00155	CbGpPWpGaD
Rasagiline—BCL2—Immune System—CAPZA1—esophageal cancer	0.000195	0.00155	CbGpPWpGaD
Rasagiline—Skin disorder—Cisplatin—esophageal cancer	0.000194	0.00197	CcSEcCtD
Rasagiline—Eye disorder—Capecitabine—esophageal cancer	0.000194	0.00197	CcSEcCtD
Rasagiline—BCL2—Integrated Pancreatic Cancer Pathway—ABL1—esophageal cancer	0.000194	0.00153	CbGpPWpGaD
Rasagiline—CYP1A2—Phase 1 - Functionalization of compounds—CYP26A1—esophageal cancer	0.000193	0.00153	CbGpPWpGaD
Rasagiline—Hyperhidrosis—Cisplatin—esophageal cancer	0.000193	0.00196	CcSEcCtD
Rasagiline—Asthma—Methotrexate—esophageal cancer	0.000193	0.00196	CcSEcCtD
Rasagiline—Cardiac disorder—Capecitabine—esophageal cancer	0.000193	0.00196	CcSEcCtD
Rasagiline—Anorexia—Cisplatin—esophageal cancer	0.000191	0.00194	CcSEcCtD
Rasagiline—Angiopathy—Capecitabine—esophageal cancer	0.000188	0.00191	CcSEcCtD
Rasagiline—BCL2—Integrated Pancreatic Cancer Pathway—SMAD4—esophageal cancer	0.000188	0.00149	CbGpPWpGaD
Rasagiline—BCL2—Integrated Pancreatic Cancer Pathway—ABCB1—esophageal cancer	0.000188	0.00149	CbGpPWpGaD
Rasagiline—Immune system disorder—Capecitabine—esophageal cancer	0.000188	0.0019	CcSEcCtD
Rasagiline—Mediastinal disorder—Capecitabine—esophageal cancer	0.000187	0.0019	CcSEcCtD
Rasagiline—Hypotension—Cisplatin—esophageal cancer	0.000187	0.0019	CcSEcCtD
Rasagiline—CYP1A2—Arachidonic acid metabolism—PTGS1—esophageal cancer	0.000187	0.00148	CbGpPWpGaD
Rasagiline—Chills—Capecitabine—esophageal cancer	0.000186	0.00189	CcSEcCtD
Rasagiline—BCL2—Direct p53 effectors—MET—esophageal cancer	0.000184	0.00146	CbGpPWpGaD
Rasagiline—Alopecia—Capecitabine—esophageal cancer	0.000183	0.00186	CcSEcCtD
Rasagiline—Musculoskeletal discomfort—Cisplatin—esophageal cancer	0.000182	0.00185	CcSEcCtD
Rasagiline—Mental disorder—Capecitabine—esophageal cancer	0.000182	0.00185	CcSEcCtD
Rasagiline—BCL2—Signaling events mediated by Stem cell factor receptor (c-Kit)—PIK3CA—esophageal cancer	0.000182	0.00144	CbGpPWpGaD
Rasagiline—BCL2—Validated targets of C-MYC transcriptional repression—MYC—esophageal cancer	0.000181	0.00143	CbGpPWpGaD
Rasagiline—Malnutrition—Capecitabine—esophageal cancer	0.000181	0.00183	CcSEcCtD
Rasagiline—Dysuria—Methotrexate—esophageal cancer	0.000181	0.00183	CcSEcCtD
Rasagiline—Paraesthesia—Cisplatin—esophageal cancer	0.00018	0.00182	CcSEcCtD
Rasagiline—Upper respiratory tract infection—Methotrexate—esophageal cancer	0.000179	0.00182	CcSEcCtD
Rasagiline—BCL2—C-MYB transcription factor network—CCND1—esophageal cancer	0.000179	0.00142	CbGpPWpGaD
Rasagiline—Dyspnoea—Cisplatin—esophageal cancer	0.000178	0.00181	CcSEcCtD
Rasagiline—Flatulence—Capecitabine—esophageal cancer	0.000178	0.00181	CcSEcCtD
Rasagiline—Erectile dysfunction—Methotrexate—esophageal cancer	0.000178	0.0018	CcSEcCtD
Rasagiline—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCB1—esophageal cancer	0.000178	0.00141	CbGpPWpGaD
Rasagiline—BCL2—Integrated Pancreatic Cancer Pathway—BAX—esophageal cancer	0.000178	0.00141	CbGpPWpGaD
Rasagiline—BCL2—Senescence and Autophagy in Cancer—CDKN2A—esophageal cancer	0.000177	0.0014	CbGpPWpGaD
Rasagiline—Dysgeusia—Capecitabine—esophageal cancer	0.000177	0.0018	CcSEcCtD
Rasagiline—Photosensitivity reaction—Methotrexate—esophageal cancer	0.000176	0.00179	CcSEcCtD
Rasagiline—Back pain—Capecitabine—esophageal cancer	0.000175	0.00177	CcSEcCtD
Rasagiline—Decreased appetite—Cisplatin—esophageal cancer	0.000174	0.00177	CcSEcCtD
Rasagiline—Muscle spasms—Capecitabine—esophageal cancer	0.000174	0.00176	CcSEcCtD
Rasagiline—BCL2—IL2-mediated signaling events—PIK3CA—esophageal cancer	0.000174	0.00137	CbGpPWpGaD
Rasagiline—BCL2—C-MYB transcription factor network—CDKN1A—esophageal cancer	0.000173	0.00137	CbGpPWpGaD
Rasagiline—Gastrointestinal disorder—Cisplatin—esophageal cancer	0.000173	0.00175	CcSEcCtD
Rasagiline—Infestation—Methotrexate—esophageal cancer	0.000172	0.00175	CcSEcCtD
Rasagiline—Infestation NOS—Methotrexate—esophageal cancer	0.000172	0.00175	CcSEcCtD
Rasagiline—BCL2—DNA Damage Response (only ATM dependent)—CDKN2A—esophageal cancer	0.000172	0.00136	CbGpPWpGaD
Rasagiline—Depression—Methotrexate—esophageal cancer	0.000172	0.00174	CcSEcCtD
Rasagiline—CYP1A2—Cytochrome P450 - arranged by substrate type—CYP2A6—esophageal cancer	0.00017	0.00135	CbGpPWpGaD
Rasagiline—CYP1A2—Tryptophan metabolism—CYP1B1—esophageal cancer	0.00017	0.00134	CbGpPWpGaD
Rasagiline—CYP1A2—Aryl Hydrocarbon Receptor Pathway—CYP1B1—esophageal cancer	0.00017	0.00134	CbGpPWpGaD
Rasagiline—CYP1A2—Aryl Hydrocarbon Receptor—CYP1B1—esophageal cancer	0.00017	0.00134	CbGpPWpGaD
Rasagiline—Tremor—Capecitabine—esophageal cancer	0.000169	0.00172	CcSEcCtD
Rasagiline—Stomatitis—Methotrexate—esophageal cancer	0.000168	0.0017	CcSEcCtD
Rasagiline—CYP1A2—Oxidation by Cytochrome P450—CYP2A6—esophageal cancer	0.000168	0.00133	CbGpPWpGaD
Rasagiline—Ill-defined disorder—Capecitabine—esophageal cancer	0.000168	0.0017	CcSEcCtD
Rasagiline—Conjunctivitis—Methotrexate—esophageal cancer	0.000167	0.0017	CcSEcCtD
Rasagiline—Anaemia—Capecitabine—esophageal cancer	0.000167	0.0017	CcSEcCtD
Rasagiline—Sweating—Methotrexate—esophageal cancer	0.000165	0.00167	CcSEcCtD
Rasagiline—Feeling abnormal—Cisplatin—esophageal cancer	0.000165	0.00167	CcSEcCtD
Rasagiline—BCL2—C-MYB transcription factor network—EP300—esophageal cancer	0.000165	0.00131	CbGpPWpGaD
Rasagiline—BCL2—DNA Damage Response (only ATM dependent)—ERBB2—esophageal cancer	0.000164	0.0013	CbGpPWpGaD
Rasagiline—Haematuria—Methotrexate—esophageal cancer	0.000164	0.00167	CcSEcCtD
Rasagiline—CYP1A2—Phase II conjugation—GSTO1—esophageal cancer	0.000163	0.00129	CbGpPWpGaD
Rasagiline—Malaise—Capecitabine—esophageal cancer	0.000163	0.00165	CcSEcCtD
Rasagiline—Epistaxis—Methotrexate—esophageal cancer	0.000162	0.00165	CcSEcCtD
Rasagiline—Vertigo—Capecitabine—esophageal cancer	0.000162	0.00165	CcSEcCtD
Rasagiline—Syncope—Capecitabine—esophageal cancer	0.000162	0.00164	CcSEcCtD
Rasagiline—Leukopenia—Capecitabine—esophageal cancer	0.000162	0.00164	CcSEcCtD
Rasagiline—BCL2—Direct p53 effectors—CREBBP—esophageal cancer	0.000161	0.00127	CbGpPWpGaD
Rasagiline—BCL2—Direct p53 effectors—RB1—esophageal cancer	0.00016	0.00127	CbGpPWpGaD
Rasagiline—CYP1A2—Tryptophan metabolism—CYP19A1—esophageal cancer	0.000159	0.00126	CbGpPWpGaD
Rasagiline—Loss of consciousness—Capecitabine—esophageal cancer	0.000159	0.00161	CcSEcCtD
Rasagiline—CYP1A2—Arachidonic acid metabolism—CYP1B1—esophageal cancer	0.000159	0.00126	CbGpPWpGaD
Rasagiline—Body temperature increased—Cisplatin—esophageal cancer	0.000158	0.00161	CcSEcCtD
Rasagiline—Cough—Capecitabine—esophageal cancer	0.000158	0.0016	CcSEcCtD
Rasagiline—Hypertension—Capecitabine—esophageal cancer	0.000156	0.00158	CcSEcCtD
Rasagiline—BCL2—Innate Immune System—ELMO1—esophageal cancer	0.000156	0.00123	CbGpPWpGaD
Rasagiline—Haemoglobin—Methotrexate—esophageal cancer	0.000155	0.00158	CcSEcCtD
Rasagiline—Haemorrhage—Methotrexate—esophageal cancer	0.000155	0.00157	CcSEcCtD
Rasagiline—BCL2—Immune System—TMEM173—esophageal cancer	0.000154	0.00122	CbGpPWpGaD
Rasagiline—Arthralgia—Capecitabine—esophageal cancer	0.000154	0.00156	CcSEcCtD
Rasagiline—Chest pain—Capecitabine—esophageal cancer	0.000154	0.00156	CcSEcCtD
Rasagiline—Anxiety—Capecitabine—esophageal cancer	0.000153	0.00156	CcSEcCtD
Rasagiline—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—esophageal cancer	0.000153	0.00155	CcSEcCtD
Rasagiline—Urinary tract disorder—Methotrexate—esophageal cancer	0.000153	0.00155	CcSEcCtD
Rasagiline—BCL2—Integrated Breast Cancer Pathway—CASP8—esophageal cancer	0.000152	0.0012	CbGpPWpGaD
Rasagiline—Discomfort—Capecitabine—esophageal cancer	0.000152	0.00154	CcSEcCtD
Rasagiline—Urethral disorder—Methotrexate—esophageal cancer	0.000152	0.00154	CcSEcCtD
Rasagiline—BCL2—Integrated Breast Cancer Pathway—RB1—esophageal cancer	0.000151	0.00119	CbGpPWpGaD
Rasagiline—Dry mouth—Capecitabine—esophageal cancer	0.00015	0.00153	CcSEcCtD
Rasagiline—BCL2—Apoptosis—CASP8—esophageal cancer	0.000149	0.00118	CbGpPWpGaD
Rasagiline—Confusional state—Capecitabine—esophageal cancer	0.000149	0.00151	CcSEcCtD
Rasagiline—BCL2—Focal Adhesion—KDR—esophageal cancer	0.000147	0.00117	CbGpPWpGaD
Rasagiline—Hypersensitivity—Cisplatin—esophageal cancer	0.000147	0.0015	CcSEcCtD
Rasagiline—CYP1A2—Phase 1 - Functionalization of compounds—ALDH2—esophageal cancer	0.000147	0.00116	CbGpPWpGaD
Rasagiline—Infection—Capecitabine—esophageal cancer	0.000147	0.00149	CcSEcCtD
Rasagiline—BCL2—DNA Damage Response (only ATM dependent)—CCND1—esophageal cancer	0.000145	0.00115	CbGpPWpGaD
Rasagiline—Shock—Capecitabine—esophageal cancer	0.000145	0.00147	CcSEcCtD
Rasagiline—BCL2—Senescence and Autophagy in Cancer—CDKN1A—esophageal cancer	0.000145	0.00115	CbGpPWpGaD
Rasagiline—Nervous system disorder—Capecitabine—esophageal cancer	0.000145	0.00147	CcSEcCtD
Rasagiline—Eye disorder—Methotrexate—esophageal cancer	0.000144	0.00147	CcSEcCtD
Rasagiline—BCL2—Focal Adhesion—MET—esophageal cancer	0.000144	0.00114	CbGpPWpGaD
Rasagiline—BCL2—C-MYB transcription factor network—MYC—esophageal cancer	0.000144	0.00114	CbGpPWpGaD
Rasagiline—BCL2—Apoptosis—MYC—esophageal cancer	0.000144	0.00114	CbGpPWpGaD
Rasagiline—Asthenia—Cisplatin—esophageal cancer	0.000144	0.00146	CcSEcCtD
Rasagiline—Cardiac disorder—Methotrexate—esophageal cancer	0.000143	0.00146	CcSEcCtD
Rasagiline—Skin disorder—Capecitabine—esophageal cancer	0.000143	0.00145	CcSEcCtD
Rasagiline—Hyperhidrosis—Capecitabine—esophageal cancer	0.000143	0.00145	CcSEcCtD
Rasagiline—Anorexia—Capecitabine—esophageal cancer	0.000141	0.00143	CcSEcCtD
Rasagiline—BCL2—DNA Damage Response (only ATM dependent)—CDKN1A—esophageal cancer	0.000141	0.00111	CbGpPWpGaD
Rasagiline—BCL2—Innate Immune System—CFL1—esophageal cancer	0.000141	0.00111	CbGpPWpGaD
Rasagiline—Angiopathy—Methotrexate—esophageal cancer	0.00014	0.00142	CcSEcCtD
Rasagiline—Immune system disorder—Methotrexate—esophageal cancer	0.00014	0.00142	CcSEcCtD
Rasagiline—Mediastinal disorder—Methotrexate—esophageal cancer	0.000139	0.00141	CcSEcCtD
Rasagiline—Chills—Methotrexate—esophageal cancer	0.000139	0.00141	CcSEcCtD
Rasagiline—CYP1A2—Phase 1 - Functionalization of compounds—CYP2A6—esophageal cancer	0.000138	0.00109	CbGpPWpGaD
Rasagiline—Hypotension—Capecitabine—esophageal cancer	0.000138	0.0014	CcSEcCtD
Rasagiline—CYP1A2—Cytochrome P450 - arranged by substrate type—CYP1B1—esophageal cancer	0.000137	0.00109	CbGpPWpGaD
Rasagiline—Diarrhoea—Cisplatin—esophageal cancer	0.000137	0.00139	CcSEcCtD
Rasagiline—Alopecia—Methotrexate—esophageal cancer	0.000137	0.00139	CcSEcCtD
Rasagiline—Mental disorder—Methotrexate—esophageal cancer	0.000135	0.00137	CcSEcCtD
Rasagiline—CYP1A2—Oxidation by Cytochrome P450—CYP1B1—esophageal cancer	0.000135	0.00107	CbGpPWpGaD
Rasagiline—BCL2—Innate Immune System—LGALS3—esophageal cancer	0.000135	0.00107	CbGpPWpGaD
Rasagiline—Malnutrition—Methotrexate—esophageal cancer	0.000135	0.00137	CcSEcCtD
Rasagiline—Musculoskeletal discomfort—Capecitabine—esophageal cancer	0.000134	0.00136	CcSEcCtD
Rasagiline—Insomnia—Capecitabine—esophageal cancer	0.000133	0.00135	CcSEcCtD
Rasagiline—Paraesthesia—Capecitabine—esophageal cancer	0.000132	0.00134	CcSEcCtD
Rasagiline—CYP1A2—Aryl Hydrocarbon Receptor Pathway—BAX—esophageal cancer	0.000132	0.00105	CbGpPWpGaD
Rasagiline—Dysgeusia—Methotrexate—esophageal cancer	0.000132	0.00134	CcSEcCtD
Rasagiline—Dyspnoea—Capecitabine—esophageal cancer	0.000132	0.00133	CcSEcCtD
Rasagiline—CYP1A2—Phase 1 - Functionalization of compounds—PTGS1—esophageal cancer	0.000131	0.00104	CbGpPWpGaD
Rasagiline—Back pain—Methotrexate—esophageal cancer	0.00013	0.00132	CcSEcCtD
Rasagiline—Dyspepsia—Capecitabine—esophageal cancer	0.00013	0.00132	CcSEcCtD
Rasagiline—BCL2—Immune System—MAP3K3—esophageal cancer	0.000129	0.00103	CbGpPWpGaD
Rasagiline—CYP1A2—Cytochrome P450 - arranged by substrate type—CYP19A1—esophageal cancer	0.000129	0.00102	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—BLVRB—esophageal cancer	0.000129	0.00102	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—SLC52A3—esophageal cancer	0.000129	0.00102	CbGpPWpGaD
Rasagiline—Decreased appetite—Capecitabine—esophageal cancer	0.000128	0.0013	CcSEcCtD
Rasagiline—Gastrointestinal disorder—Capecitabine—esophageal cancer	0.000127	0.00129	CcSEcCtD
Rasagiline—Vomiting—Cisplatin—esophageal cancer	0.000127	0.00129	CcSEcCtD
Rasagiline—CYP1A2—Oxidation by Cytochrome P450—CYP19A1—esophageal cancer	0.000127	0.00101	CbGpPWpGaD
Rasagiline—CYP1A2—Phase II conjugation—GSTT1—esophageal cancer	0.000127	0.001	CbGpPWpGaD
Rasagiline—Rash—Cisplatin—esophageal cancer	0.000126	0.00128	CcSEcCtD
Rasagiline—Constipation—Capecitabine—esophageal cancer	0.000126	0.00128	CcSEcCtD
Rasagiline—CYP1A2—Biological oxidations—ADH7—esophageal cancer	0.000126	0.000998	CbGpPWpGaD
Rasagiline—Dermatitis—Cisplatin—esophageal cancer	0.000126	0.00128	CcSEcCtD
Rasagiline—BCL2—Integrated Pancreatic Cancer Pathway—CASP8—esophageal cancer	0.000126	0.000998	CbGpPWpGaD
Rasagiline—BCL2—Integrated Pancreatic Cancer Pathway—CREBBP—esophageal cancer	0.000125	0.000993	CbGpPWpGaD
Rasagiline—Ill-defined disorder—Methotrexate—esophageal cancer	0.000125	0.00127	CcSEcCtD
Rasagiline—Anaemia—Methotrexate—esophageal cancer	0.000124	0.00126	CcSEcCtD
Rasagiline—Feeling abnormal—Capecitabine—esophageal cancer	0.000122	0.00123	CcSEcCtD
Rasagiline—Malaise—Methotrexate—esophageal cancer	0.000121	0.00123	CcSEcCtD
Rasagiline—Vertigo—Methotrexate—esophageal cancer	0.000121	0.00123	CcSEcCtD
Rasagiline—Gastrointestinal pain—Capecitabine—esophageal cancer	0.000121	0.00122	CcSEcCtD
Rasagiline—Leukopenia—Methotrexate—esophageal cancer	0.00012	0.00122	CcSEcCtD
Rasagiline—BCL2—Innate Immune System—ACTB—esophageal cancer	0.00012	0.000947	CbGpPWpGaD
Rasagiline—Nausea—Cisplatin—esophageal cancer	0.000119	0.00121	CcSEcCtD
Rasagiline—BCL2—Apoptosis—TP53—esophageal cancer	0.000118	0.000934	CbGpPWpGaD
Rasagiline—Cough—Methotrexate—esophageal cancer	0.000117	0.00119	CcSEcCtD
Rasagiline—Urticaria—Capecitabine—esophageal cancer	0.000117	0.00119	CcSEcCtD
Rasagiline—Body temperature increased—Capecitabine—esophageal cancer	0.000117	0.00118	CcSEcCtD
Rasagiline—Abdominal pain—Capecitabine—esophageal cancer	0.000117	0.00118	CcSEcCtD
Rasagiline—BCL2—DNA Damage Response (only ATM dependent)—MYC—esophageal cancer	0.000117	0.000923	CbGpPWpGaD
Rasagiline—Convulsion—Methotrexate—esophageal cancer	0.000117	0.00118	CcSEcCtD
Rasagiline—BCL2—Innate Immune System—B2M—esophageal cancer	0.000115	0.000914	CbGpPWpGaD
Rasagiline—BCL2—Direct p53 effectors—CDKN1A—esophageal cancer	0.000115	0.000911	CbGpPWpGaD
Rasagiline—Chest pain—Methotrexate—esophageal cancer	0.000115	0.00116	CcSEcCtD
Rasagiline—Arthralgia—Methotrexate—esophageal cancer	0.000115	0.00116	CcSEcCtD
Rasagiline—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—esophageal cancer	0.000114	0.00115	CcSEcCtD
Rasagiline—Discomfort—Methotrexate—esophageal cancer	0.000113	0.00115	CcSEcCtD
Rasagiline—BCL2—Integrated Breast Cancer Pathway—CCND1—esophageal cancer	0.000112	0.000887	CbGpPWpGaD
Rasagiline—CYP1A2—Phase 1 - Functionalization of compounds—CYP1B1—esophageal cancer	0.000111	0.00088	CbGpPWpGaD
Rasagiline—Confusional state—Methotrexate—esophageal cancer	0.000111	0.00112	CcSEcCtD
Rasagiline—BCL2—Apoptosis Modulation and Signaling—TP53—esophageal cancer	0.000111	0.000876	CbGpPWpGaD
Rasagiline—CYP1A2—Biological oxidations—ADH1B—esophageal cancer	0.000111	0.000876	CbGpPWpGaD
Rasagiline—BCL2—Immune System—CTSC—esophageal cancer	0.00011	0.000872	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—SLC10A2—esophageal cancer	0.00011	0.000868	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—CA1—esophageal cancer	0.00011	0.000868	CbGpPWpGaD
Rasagiline—BCL2—Direct p53 effectors—EP300—esophageal cancer	0.00011	0.000867	CbGpPWpGaD
Rasagiline—Infection—Methotrexate—esophageal cancer	0.000109	0.00111	CcSEcCtD
Rasagiline—Hypersensitivity—Capecitabine—esophageal cancer	0.000109	0.0011	CcSEcCtD
Rasagiline—Nervous system disorder—Methotrexate—esophageal cancer	0.000108	0.00109	CcSEcCtD
Rasagiline—Skin disorder—Methotrexate—esophageal cancer	0.000107	0.00108	CcSEcCtD
Rasagiline—Hyperhidrosis—Methotrexate—esophageal cancer	0.000106	0.00108	CcSEcCtD
Rasagiline—Asthenia—Capecitabine—esophageal cancer	0.000106	0.00107	CcSEcCtD
Rasagiline—BCL2—Focal Adhesion—ERBB2—esophageal cancer	0.000105	0.000835	CbGpPWpGaD
Rasagiline—BCL2—Integrated Pancreatic Cancer Pathway—ERBB2—esophageal cancer	0.000105	0.000832	CbGpPWpGaD
Rasagiline—Anorexia—Methotrexate—esophageal cancer	0.000105	0.00106	CcSEcCtD
Rasagiline—CYP1A2—Phase 1 - Functionalization of compounds—CYP19A1—esophageal cancer	0.000104	0.000827	CbGpPWpGaD
Rasagiline—Pruritus—Capecitabine—esophageal cancer	0.000104	0.00106	CcSEcCtD
Rasagiline—BCL2—Integrated Breast Cancer Pathway—EP300—esophageal cancer	0.000103	0.000816	CbGpPWpGaD
Rasagiline—CYP1A2—Biological oxidations—CYP26A1—esophageal cancer	0.000103	0.000814	CbGpPWpGaD
Rasagiline—BCL2—Integrated Pancreatic Cancer Pathway—PTGS2—esophageal cancer	0.000103	0.000813	CbGpPWpGaD
Rasagiline—Hypotension—Methotrexate—esophageal cancer	0.000103	0.00104	CcSEcCtD
Rasagiline—CYP1A2—Metapathway biotransformation—CYP26A1—esophageal cancer	0.000101	0.000803	CbGpPWpGaD
Rasagiline—Diarrhoea—Capecitabine—esophageal cancer	0.000101	0.00102	CcSEcCtD
Rasagiline—MAOB—Metabolism—CA2—esophageal cancer	0.0001	0.000794	CbGpPWpGaD
Rasagiline—Musculoskeletal discomfort—Methotrexate—esophageal cancer	0.0001	0.00102	CcSEcCtD
Rasagiline—Insomnia—Methotrexate—esophageal cancer	9.93e-05	0.00101	CcSEcCtD
Rasagiline—BCL2—DNA Damage Response (only ATM dependent)—PIK3CA—esophageal cancer	9.9e-05	0.000784	CbGpPWpGaD
Rasagiline—BCL2—Senescence and Autophagy in Cancer—TP53—esophageal cancer	9.86e-05	0.000781	CbGpPWpGaD
Rasagiline—Paraesthesia—Methotrexate—esophageal cancer	9.86e-05	0.001	CcSEcCtD
Rasagiline—Dyspnoea—Methotrexate—esophageal cancer	9.79e-05	0.000993	CcSEcCtD
Rasagiline—Somnolence—Methotrexate—esophageal cancer	9.76e-05	0.000991	CcSEcCtD
Rasagiline—Dizziness—Capecitabine—esophageal cancer	9.75e-05	0.00099	CcSEcCtD
Rasagiline—BCL2—Innate Immune System—HMGB1—esophageal cancer	9.67e-05	0.000766	CbGpPWpGaD
Rasagiline—Dyspepsia—Methotrexate—esophageal cancer	9.67e-05	0.000981	CcSEcCtD
Rasagiline—BCL2—DNA Damage Response (only ATM dependent)—TP53—esophageal cancer	9.57e-05	0.000758	CbGpPWpGaD
Rasagiline—CYP1A2—Biological oxidations—GSTO1—esophageal cancer	9.55e-05	0.000757	CbGpPWpGaD
Rasagiline—Decreased appetite—Methotrexate—esophageal cancer	9.55e-05	0.000969	CcSEcCtD
Rasagiline—Gastrointestinal disorder—Methotrexate—esophageal cancer	9.48e-05	0.000962	CcSEcCtD
Rasagiline—CYP1A2—Metapathway biotransformation—GSTO1—esophageal cancer	9.42e-05	0.000746	CbGpPWpGaD
Rasagiline—Vomiting—Capecitabine—esophageal cancer	9.38e-05	0.000952	CcSEcCtD
Rasagiline—BCL2—Direct p53 effectors—EGFR—esophageal cancer	9.33e-05	0.000739	CbGpPWpGaD
Rasagiline—BCL2—Focal Adhesion—CCND1—esophageal cancer	9.32e-05	0.000738	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—PLCE1—esophageal cancer	9.32e-05	0.000738	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—ADH7—esophageal cancer	9.32e-05	0.000738	CbGpPWpGaD
Rasagiline—Rash—Capecitabine—esophageal cancer	9.3e-05	0.000944	CcSEcCtD
Rasagiline—CYP1A2—Aryl Hydrocarbon Receptor—RB1—esophageal cancer	9.3e-05	0.000736	CbGpPWpGaD
Rasagiline—Dermatitis—Capecitabine—esophageal cancer	9.29e-05	0.000943	CcSEcCtD
Rasagiline—BCL2—Integrated Pancreatic Cancer Pathway—CCND1—esophageal cancer	9.28e-05	0.000735	CbGpPWpGaD
Rasagiline—Headache—Capecitabine—esophageal cancer	9.24e-05	0.000938	CcSEcCtD
Rasagiline—BCL2—Immune System—ELMO1—esophageal cancer	9.08e-05	0.000719	CbGpPWpGaD
Rasagiline—Feeling abnormal—Methotrexate—esophageal cancer	9.05e-05	0.000918	CcSEcCtD
Rasagiline—BCL2—Integrated Breast Cancer Pathway—MYC—esophageal cancer	8.98e-05	0.000711	CbGpPWpGaD
Rasagiline—Gastrointestinal pain—Methotrexate—esophageal cancer	8.98e-05	0.000911	CcSEcCtD
Rasagiline—BCL2—Integrated Pancreatic Cancer Pathway—CDKN1A—esophageal cancer	8.98e-05	0.000711	CbGpPWpGaD
Rasagiline—BCL2—Integrated Breast Cancer Pathway—EGFR—esophageal cancer	8.79e-05	0.000696	CbGpPWpGaD
Rasagiline—Nausea—Capecitabine—esophageal cancer	8.76e-05	0.000889	CcSEcCtD
Rasagiline—Urticaria—Methotrexate—esophageal cancer	8.72e-05	0.000885	CcSEcCtD
Rasagiline—Abdominal pain—Methotrexate—esophageal cancer	8.68e-05	0.000881	CcSEcCtD
Rasagiline—Body temperature increased—Methotrexate—esophageal cancer	8.68e-05	0.000881	CcSEcCtD
Rasagiline—BCL2—Integrated Pancreatic Cancer Pathway—EP300—esophageal cancer	8.54e-05	0.000676	CbGpPWpGaD
Rasagiline—BCL2—Immune System—CFL1—esophageal cancer	8.19e-05	0.000648	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—ADH1B—esophageal cancer	8.17e-05	0.000647	CbGpPWpGaD
Rasagiline—Hypersensitivity—Methotrexate—esophageal cancer	8.09e-05	0.000821	CcSEcCtD
Rasagiline—BCL2—Innate Immune System—ABL1—esophageal cancer	8e-05	0.000634	CbGpPWpGaD
Rasagiline—Asthenia—Methotrexate—esophageal cancer	7.88e-05	0.000799	CcSEcCtD
Rasagiline—BCL2—Immune System—LGALS3—esophageal cancer	7.84e-05	0.000621	CbGpPWpGaD
Rasagiline—BCL2—Direct p53 effectors—TP53—esophageal cancer	7.84e-05	0.000621	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—TYMP—esophageal cancer	7.81e-05	0.000618	CbGpPWpGaD
Rasagiline—CYP1A2—Biological oxidations—ALDH2—esophageal cancer	7.79e-05	0.000617	CbGpPWpGaD
Rasagiline—Pruritus—Methotrexate—esophageal cancer	7.77e-05	0.000788	CcSEcCtD
Rasagiline—CYP1A2—Aryl Hydrocarbon Receptor—PTGS2—esophageal cancer	7.64e-05	0.000605	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—CYP26A1—esophageal cancer	7.59e-05	0.000601	CbGpPWpGaD
Rasagiline—Diarrhoea—Methotrexate—esophageal cancer	7.51e-05	0.000762	CcSEcCtD
Rasagiline—BCL2—Integrated Pancreatic Cancer Pathway—MYC—esophageal cancer	7.44e-05	0.000589	CbGpPWpGaD
Rasagiline—CYP1A2—Biological oxidations—GSTT1—esophageal cancer	7.41e-05	0.000587	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—ALOX15—esophageal cancer	7.4e-05	0.000586	CbGpPWpGaD
Rasagiline—BCL2—Integrated Breast Cancer Pathway—TP53—esophageal cancer	7.38e-05	0.000584	CbGpPWpGaD
Rasagiline—CYP1A2—Biological oxidations—CYP2A6—esophageal cancer	7.32e-05	0.00058	CbGpPWpGaD
Rasagiline—BCL2—Focal Adhesion—EGFR—esophageal cancer	7.31e-05	0.000579	CbGpPWpGaD
Rasagiline—BCL2—Integrated Pancreatic Cancer Pathway—EGFR—esophageal cancer	7.28e-05	0.000577	CbGpPWpGaD
Rasagiline—Dizziness—Methotrexate—esophageal cancer	7.26e-05	0.000737	CcSEcCtD
Rasagiline—BCL2—Apoptosis—TP53—esophageal cancer	7.22e-05	0.000572	CbGpPWpGaD
Rasagiline—CYP1A2—Arachidonic acid metabolism—PTGS2—esophageal cancer	7.15e-05	0.000566	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—GSTO1—esophageal cancer	7.06e-05	0.000559	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—TPI1—esophageal cancer	7.06e-05	0.000559	CbGpPWpGaD
Rasagiline—Vomiting—Methotrexate—esophageal cancer	6.98e-05	0.000708	CcSEcCtD
Rasagiline—BCL2—Immune System—ACTB—esophageal cancer	6.96e-05	0.000551	CbGpPWpGaD
Rasagiline—CYP1A2—Biological oxidations—PTGS1—esophageal cancer	6.94e-05	0.00055	CbGpPWpGaD
Rasagiline—Rash—Methotrexate—esophageal cancer	6.92e-05	0.000703	CcSEcCtD
Rasagiline—Dermatitis—Methotrexate—esophageal cancer	6.92e-05	0.000702	CcSEcCtD
Rasagiline—Headache—Methotrexate—esophageal cancer	6.88e-05	0.000698	CcSEcCtD
Rasagiline—BCL2—Immune System—PTPN2—esophageal cancer	6.8e-05	0.000538	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—ALDOB—esophageal cancer	6.77e-05	0.000536	CbGpPWpGaD
Rasagiline—BCL2—Immune System—B2M—esophageal cancer	6.72e-05	0.000532	CbGpPWpGaD
Rasagiline—CYP1A2—Aryl Hydrocarbon Receptor—CDKN1A—esophageal cancer	6.68e-05	0.000529	CbGpPWpGaD
Rasagiline—Nausea—Methotrexate—esophageal cancer	6.52e-05	0.000662	CcSEcCtD
Rasagiline—MAOB—Metabolism—GAPDH—esophageal cancer	6.52e-05	0.000516	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—CRABP1—esophageal cancer	6.46e-05	0.000511	CbGpPWpGaD
Rasagiline—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EP300—esophageal cancer	6.35e-05	0.000503	CbGpPWpGaD
Rasagiline—CYP1A2—Aryl Hydrocarbon Receptor—EP300—esophageal cancer	6.35e-05	0.000503	CbGpPWpGaD
Rasagiline—BCL2—Immune System—PSME2—esophageal cancer	6.35e-05	0.000503	CbGpPWpGaD
Rasagiline—BCL2—Immune System—PSME1—esophageal cancer	6.35e-05	0.000503	CbGpPWpGaD
Rasagiline—BCL2—Focal Adhesion—PIK3CA—esophageal cancer	6.34e-05	0.000502	CbGpPWpGaD
Rasagiline—BCL2—Integrated Pancreatic Cancer Pathway—PIK3CA—esophageal cancer	6.32e-05	0.0005	CbGpPWpGaD
Rasagiline—BCL2—Immune System—HSPA5—esophageal cancer	6.29e-05	0.000498	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—GNG7—esophageal cancer	6.14e-05	0.000486	CbGpPWpGaD
Rasagiline—BCL2—Integrated Pancreatic Cancer Pathway—TP53—esophageal cancer	6.11e-05	0.000484	CbGpPWpGaD
Rasagiline—BCL2—Immune System—CALR—esophageal cancer	6.09e-05	0.000483	CbGpPWpGaD
Rasagiline—BCL2—Innate Immune System—TLR4—esophageal cancer	6.06e-05	0.00048	CbGpPWpGaD
Rasagiline—CYP1A2—Biological oxidations—CYP1B1—esophageal cancer	5.9e-05	0.000467	CbGpPWpGaD
Rasagiline—BCL2—Immune System—FBXW7—esophageal cancer	5.89e-05	0.000467	CbGpPWpGaD
Rasagiline—CYP1A2—Metapathway biotransformation—CYP1B1—esophageal cancer	5.82e-05	0.000461	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—ALDH2—esophageal cancer	5.76e-05	0.000456	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism of lipids and lipoproteins—SLC10A2—esophageal cancer	5.69e-05	0.000451	CbGpPWpGaD
Rasagiline—BCL2—Immune System—HMGB1—esophageal cancer	5.63e-05	0.000446	CbGpPWpGaD
Rasagiline—CYP1A2—Biological oxidations—CYP19A1—esophageal cancer	5.55e-05	0.00044	CbGpPWpGaD
Rasagiline—CYP1A2—Aryl Hydrocarbon Receptor—MYC—esophageal cancer	5.54e-05	0.000439	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—GSTT1—esophageal cancer	5.47e-05	0.000434	CbGpPWpGaD
Rasagiline—CYP1A2—Metapathway biotransformation—CYP19A1—esophageal cancer	5.47e-05	0.000433	CbGpPWpGaD
Rasagiline—CYP1A2—Aryl Hydrocarbon Receptor—EGFR—esophageal cancer	5.42e-05	0.000429	CbGpPWpGaD
Rasagiline—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EGFR—esophageal cancer	5.42e-05	0.000429	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—CYP2A6—esophageal cancer	5.41e-05	0.000429	CbGpPWpGaD
Rasagiline—BCL2—Innate Immune System—CASP8—esophageal cancer	5.2e-05	0.000412	CbGpPWpGaD
Rasagiline—BCL2—Innate Immune System—CREBBP—esophageal cancer	5.18e-05	0.00041	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—PTGS1—esophageal cancer	5.13e-05	0.000406	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—ENO1—esophageal cancer	5.13e-05	0.000406	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—PSME2—esophageal cancer	5.05e-05	0.0004	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—PSME1—esophageal cancer	5.05e-05	0.0004	CbGpPWpGaD
Rasagiline—BCL2—Immune System—ABL1—esophageal cancer	4.66e-05	0.000369	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—CYP1B1—esophageal cancer	4.36e-05	0.000345	CbGpPWpGaD
Rasagiline—BCL2—Innate Immune System—ERBB2—esophageal cancer	4.34e-05	0.000343	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—CYP19A1—esophageal cancer	4.1e-05	0.000325	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism of lipids and lipoproteins—ALOX15—esophageal cancer	3.85e-05	0.000305	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—HMOX1—esophageal cancer	3.74e-05	0.000296	CbGpPWpGaD
Rasagiline—BCL2—Innate Immune System—CDKN1A—esophageal cancer	3.71e-05	0.000294	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—ABCB1—esophageal cancer	3.59e-05	0.000284	CbGpPWpGaD
Rasagiline—BCL2—Immune System—TLR4—esophageal cancer	3.53e-05	0.00028	CbGpPWpGaD
Rasagiline—BCL2—Innate Immune System—EP300—esophageal cancer	3.53e-05	0.000279	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism of lipids and lipoproteins—CRABP1—esophageal cancer	3.36e-05	0.000266	CbGpPWpGaD
Rasagiline—BCL2—Immune System—CASP8—esophageal cancer	3.03e-05	0.00024	CbGpPWpGaD
Rasagiline—BCL2—Immune System—CREBBP—esophageal cancer	3.02e-05	0.000239	CbGpPWpGaD
Rasagiline—BCL2—Innate Immune System—EGFR—esophageal cancer	3.01e-05	0.000238	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—BLVRB—esophageal cancer	2.98e-05	0.000236	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—SLC52A3—esophageal cancer	2.98e-05	0.000236	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism of lipids and lipoproteins—PTGS1—esophageal cancer	2.67e-05	0.000211	CbGpPWpGaD
Rasagiline—BCL2—Innate Immune System—PIK3CA—esophageal cancer	2.61e-05	0.000207	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—SLC10A2—esophageal cancer	2.54e-05	0.000201	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—CA1—esophageal cancer	2.54e-05	0.000201	CbGpPWpGaD
Rasagiline—BCL2—Immune System—ERBB2—esophageal cancer	2.53e-05	0.0002	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—CREBBP—esophageal cancer	2.4e-05	0.00019	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—CA2—esophageal cancer	2.32e-05	0.000184	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism of lipids and lipoproteins—CYP1B1—esophageal cancer	2.27e-05	0.00018	CbGpPWpGaD
Rasagiline—BCL2—Immune System—CDKN1A—esophageal cancer	2.16e-05	0.000171	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—PLCE1—esophageal cancer	2.16e-05	0.000171	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—ADH7—esophageal cancer	2.16e-05	0.000171	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—NOS3—esophageal cancer	2.15e-05	0.00017	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism of lipids and lipoproteins—CYP19A1—esophageal cancer	2.13e-05	0.000169	CbGpPWpGaD
Rasagiline—BCL2—Immune System—EP300—esophageal cancer	2.05e-05	0.000163	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—PTGS2—esophageal cancer	1.97e-05	0.000156	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—ADH1B—esophageal cancer	1.89e-05	0.00015	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—TYMP—esophageal cancer	1.81e-05	0.000143	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—CYP26A1—esophageal cancer	1.76e-05	0.000139	CbGpPWpGaD
Rasagiline—BCL2—Immune System—EGFR—esophageal cancer	1.75e-05	0.000139	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—ALOX15—esophageal cancer	1.71e-05	0.000136	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—EP300—esophageal cancer	1.63e-05	0.000129	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—GSTO1—esophageal cancer	1.63e-05	0.000129	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—TPI1—esophageal cancer	1.63e-05	0.000129	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—ALDOB—esophageal cancer	1.57e-05	0.000124	CbGpPWpGaD
Rasagiline—BCL2—Immune System—PIK3CA—esophageal cancer	1.52e-05	0.00012	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—GAPDH—esophageal cancer	1.51e-05	0.000119	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—CRABP1—esophageal cancer	1.49e-05	0.000118	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—GNG7—esophageal cancer	1.42e-05	0.000113	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—ALDH2—esophageal cancer	1.33e-05	0.000105	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—GSTT1—esophageal cancer	1.27e-05	0.0001	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—CYP2A6—esophageal cancer	1.25e-05	9.92e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism of lipids and lipoproteins—CREBBP—esophageal cancer	1.25e-05	9.88e-05	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—PIK3CA—esophageal cancer	1.21e-05	9.58e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—PTGS1—esophageal cancer	1.19e-05	9.4e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—ENO1—esophageal cancer	1.19e-05	9.4e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—PSME2—esophageal cancer	1.17e-05	9.26e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—PSME1—esophageal cancer	1.17e-05	9.26e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—esophageal cancer	1.02e-05	8.09e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—CYP1B1—esophageal cancer	1.01e-05	7.99e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—CYP19A1—esophageal cancer	9.49e-06	7.52e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—HMOX1—esophageal cancer	8.66e-06	6.86e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism of lipids and lipoproteins—EP300—esophageal cancer	8.5e-06	6.73e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—ABCB1—esophageal cancer	8.31e-06	6.58e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	6.28e-06	4.98e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—CREBBP—esophageal cancer	5.56e-06	4.4e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—NOS3—esophageal cancer	4.97e-06	3.94e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—PTGS2—esophageal cancer	4.55e-06	3.6e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—EP300—esophageal cancer	3.78e-06	3e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—PIK3CA—esophageal cancer	2.8e-06	2.22e-05	CbGpPWpGaD
